Tamoxifen, a synthetic estrogen receptor modulator, is an effective breast cancer adjuvant therapy and is also recognized as a breast cancer prevention drug for women. It also has the added benefit of reducing the risk of osteoporotic fractures. A recent metanalysis of existing trials calculated a dramatic 38 percent reduction in the incidence of breast cancer in women who used tamoxifen. However, the medication is not without significant side effects, including increased risk of endometrial cancer, pulmonary embolism, painful sexual intercourse, stroke, and cataracts. These risks fuel public debate about the drug's use in preventing breast cancer, even among high-risk women.
Understanding reasons why women decline to take tamoxifen even after education provides substantial opportunities for tailoring patient education to specific groups and developing new classes of cancer prevention drugs.
Joy Melnikow, M.D., M.P.H. of the University of California, Davis and her team interviewed 255 women with significant risk factors for breast cancer. The interview included an evidence-based education session about the risks and benefits of tamoxifen and a follow-up evaluation of their knowledge about the drug and their decision to take or not take tamoxifen.
The women in the study seriously overestimated their breast cancer risk, perceiving they were at ten times their actual risk. Despite that substantial overestimation of risk, seven out of ten (70.9 percent) described their risk a
'"/>
Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
11-Apr-2005